Clinical trial · Interventional
Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma
Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma: Safety and Efficacy
NCT03432299CI-TRIAL-00061714RFAforPTMCunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a single center prospective clinical trial with regard to efficacy and safety of radiofrequency ablation of papillary thyroid microcarcinoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Papillary Thyroid Microcarcinoma | Thyroid Gland Papillary Microcarcinoma | ALIAS | 0.90 |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RFA for PTMC | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- RFA for PTMC
- description
- Group who will undergo RFA after diagnosis of PTC
- interventionNames
- Procedure: RFA for PTMC
Primary outcomes (1)
- measure
- Change of tumor size
- timeFrame
- baseline, 2, 6, 12, 18, 24 months during the first two years after RFA, and yearly afterwards upto 10 years
- description
- Maximal dimension (mm) of ablation zone on Ultrasonography
Secondary outcomes (3)
- measure
- Development of Metastasis
- timeFrame
- baseline, 2, 6, 12, 18, 24 months during the first two years after RFA, and yearly afterwards upto 10 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * who agrees to the consent form * aged from 19 to 60 years old * who has been diagnosed with Bethesda category V or VI by fine needle aspiration or needle biopsy * whose thyroid cancer is 1 cm or smaller than 1 cm length * who does not have lymph node or distant metastasis * whose thyroid cancer does not have extrathyroidal extension * in whom it seems technically possible to completely ablate thyroid cancer using RF Exclusion Criteria: * who cannot routinely followed up according to the study schedule * who has been with Bethesda category I, II, III, or IV by fine needle aspiration or needle biopsy. * who has hyperthyroidism that requires treatment * who has bleeding tendency * multifocal papillary thyroid microcarcinoma * who is pregnant
References
Publications (1)
- DERIVEDLee JY, Na DG, Sim JS, Sung JY, Cho SW, Park DJ, Park YJ, Kim JH. A Prospective Clinical Trial of Radiofrequency Ablation in Patients with Low-Risk Unifocal Papillary Thyroid Microcarcinoma Favoring Active Surveillance Over Surgery. Thyroid. 2024 Sep;34(9):1126-1136. doi: 10.1089/thy.2024.0098. PMID 39212950